A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
Clinical trial NCT02879669 · UNKNOWN
Trial details
- NCT number
- NCT02879669
- Sponsor
- Targovax Oy
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-01
- Primary completion
- 2020-05-01
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.